DNA vaccines encoding altered forms of melanocyte differentiation antigens, such as xenogenic gp100 [53, 54], epitope enriched TRP-1 [48], and randomly mutated TRP-2 [55], have each proven effective at priming CD8 T cell responses, resulting in protective immunity against melanoma and concomitant vitiligo. The gene discussed is TYRP1; the disease is melanoma.